BLU-945 | CAS#2660250-10-0 | EGFR inhibitor

MedKoo Cat#: 207179 | Name: BLU-945

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BLU-945 is a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR inhibitor) with intracranial activity. BLU-945 demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer. BLU-945 is a potential best-in-class, selective, potent, fourth-generation EGFR TKI with activity against the EGFRm/T790M double and EGFRm/T790M/C797S triple mutants.

Chemical Structure

BLU-945

CAS#2660250-10-0

Theoretical Analysis

MedKoo Cat#: 207179

Name: BLU-945

CAS#: 2660250-10-0

Chemical Formula: C28H37FN6O3S

Exact Mass: 556.2632

Molecular Weight: 556.70

Elemental Analysis: C, 60.41; H, 6.70; F, 3.41; N, 15.10; O, 8.62; S, 5.76

Price and Availability

Size	Price	Availability
5mg	USD 90.00	Ready to ship
10mg	USD 150.00	Ready to Ship
25mg	USD 250.00	Ready to Ship
50mg	USD 450.00	Ready to Ship
100mg	USD 750.00	Ready to Ship
200mg	USD 1,350.00	Ready to Ship
500mg	USD 2,850.00	Ready to ship
1g	USD 4,550.00	Ready to Ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

BLU-945; BLU 945; BLU945; tigozertinib; tigozertinibum

IUPAC/Chemical Name

N-(2-((3S,4R)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl)-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-3-amine

InChi Key

LIMFPAAAIVQRRD-BCGVJQADSA-N

InChi Code

InChI=1S/C28H37FN6O3S/c1-17(2)20-6-7-24(35-14-19(18(35)3)16-39(5,36)37)22-13-31-27(12-21(20)22)32-26-8-10-30-28(33-26)34-11-9-25(38-4)23(29)15-34/h6-8,10,12-13,17-19,23,25H,9,11,14-16H2,1-5H3,(H,30,31,32,33)/t18-,19-,23+,25-/m1/s1

SMILES Code

CC(C1=CC=C(N2[C@@H]([C@H](C2)CS(C)(=O)=O)C)C3=C1C=C(NC4=NC(N5C[C@@H]([C@@H](CC5)OC)F)=NC=C4)N=C3)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#T23D03P20

QC Data

View QC data: current batch, Lot#T23D03P20

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

BLU-945 is a reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs).

In vitro activity:

BLU-945 (compound 30) is a potent, reversible, wild-type-sparing inhibitor of EGFR+/T790M and EGFR+/T790M/C797S resistance mutants that maintains activity against the sensitizing mutations, especially L858R. Reference: J Med Chem. 2022 Jul 28;65(14):9662-9677. https://pubmed.ncbi.nlm.nih.gov/35838760/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	112.5	202.08

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 556.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, Wilson D, Wilson K, Brooijmans N, Kim J, Özen A, Perola E, Hsieh J, Brown V, Fetalvero K, Garner A, Zhang Z, Stevison F, Woessner R, Singh J, Timsit Y, Kinkema C, Medendorp C, Lee C, Albayya F, Zalutskaya A, Schalm S, Dineen TA. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2022 Jul 28;65(14):9662-9677. doi: 10.1021/acs.jmedchem.2c00704. Epub 2022 Jul 15. PMID: 35838760; PMCID: PMC9340769.

In vitro protocol:

In vivo protocol:

TBD

1: Kannan K, Mohan S. Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs. Med Oncol. 2025 May 5;42(6):196. doi: 10.1007/s12032-025-02755-9. PMID: 40325239. 2: Zhou H, Fu H, Shao X, Cai W. Identification of novel inhibitors for epidermal growth factor receptor tyrosine kinase using absolute binding free-energy simulations. Int J Biol Macromol. 2025 Apr;304(Pt 2):140989. doi: 10.1016/j.ijbiomac.2025.140989. Epub 2025 Feb 12. PMID: 39952524. 3: Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, Albayya F, Dineen TA, Hsieh J, Oh SY, Zalutskaya A, Rotow J, Goto K, Lee DH, Yun MR, Cho BC. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib- resistant non-small-cell lung cancer. Ther Adv Med Oncol. 2024 Oct 21;16:17588359241280689. doi: 10.1177/17588359241280689. PMID: 39444426; PMCID: PMC11497503. 4: Zhou H, Fu H, Shao X, Cai W. Binding Thermodynamics of Fourth-Generation EGFR Inhibitors Revealed by Absolute Binding Free Energy Calculations. J Chem Inf Model. 2023 Dec 25;63(24):7837-7846. doi: 10.1021/acs.jcim.3c01636. Epub 2023 Dec 6. PMID: 38054791. 5: Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, Wilson D, Wilson K, Brooijmans N, Kim J, Özen A, Perola E, Hsieh J, Brown V, Fetalvero K, Garner A, Zhang Z, Stevison F, Woessner R, Singh J, Timsit Y, Kinkema C, Medendorp C, Lee C, Albayya F, Zalutskaya A, Schalm S, Dineen TA. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2022 Jul 28;65(14):9662-9677. doi: 10.1021/acs.jmedchem.2c00704. Epub 2022 Jul 15. PMID: 35838760; PMCID: PMC9340769.